Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
May 07 2024 - 8:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
innovation, today announced that it will host a conference call and
live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2024, to
review its financial results for the quarter ended March 31, 2024
and to provide a company update.
To access the conference call via phone, dial (646) 307-1963
(U.S.) or (800) 715-9871 (toll free). The conference ID number for
the call is 5582540. The live webcast can be accessed under
“Presentations, Events & Webcasts" in the Investors section of
the company's website at http://ir.darebioscience.com. Please
log in approximately 5-10 minutes prior to the call to register and
to download and install any necessary software. The webcast will be
archived under “Presentations, Events & Webcasts" in the
Investors section of the company's website
at http://ir.darebioscience.com and available for replay
until May 28, 2024.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to
advancing innovative products for women’s health. The company’s
mission is to identify, develop and bring to market a diverse
portfolio of differentiated therapies that prioritize women's
health and well-being, expand treatment options, and improve
outcomes, primarily in the areas of contraception, vaginal health,
reproductive health, menopause, sexual health and fertility.
The first FDA-approved product to emerge from Daré’s portfolio
of women’s health product candidates is XACIATO™ (clindamycin
phosphate) vaginal gel 2%, a lincosamide antibacterial indicated
for the treatment of bacterial vaginosis in female patients 12
years of age and older, which is under a global license agreement
with Organon. Organon commenced U.S. marketing of XACIATO
in the fourth quarter of 2023. Daré’s portfolio also includes
potential first-in-category candidates in clinical development:
Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive
whose U.S. commercial rights are under a license
agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream
formulation of sildenafil, the active ingredient in Viagra®, to
treat female sexual arousal disorder (FSAD); and DARE-HRT1, a
combination bio-identical estradiol and progesterone intravaginal
ring for menopausal hormone therapy. To learn more about XACIATO,
Daré’s full portfolio of women’s health product candidates, and
Daré’s mission to deliver differentiated therapies for women,
please visit www.darebioscience.com.
Daré Bioscience leadership has been named on the Medicine
Maker’s Power List and Endpoints News’ Women in Biopharma 2022. In
2023, Daré's CEO was honored as one of Fierce Pharma’s Most
Influential People in Biopharma for Daré’s contributions to
innovation and advocacy in the women’s health space. Daré
Bioscience placed #1 in the Small Company category of the
San Diego Business Journal’s 2023 Best Places to Work Awards.
Daré may announce material information about its finances,
product and product candidates, clinical trials and other matters
using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use these
channels to distribute material information about the company and
may also use social media to communicate important information
about the company, its finances, product and product candidates,
clinical trials and other matters. The information Daré posts on
its investor relations website or through social media channels may
be deemed to be material information. Daré encourages investors,
the media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these X (formerly Twitter) accounts: @SabrinaDareCEO
and @DareBioscience. Any updates to the list of social media
channels the company may use to communicate information will be
posted in the Investors section of Daré’s website.
Contacts:
Media and Investors on behalf of Daré Bioscience,
Inc:Camilla White / Simona KormanikovaDentons Global
AdvisorsDareBioscience@dentonsglobaladvisors.com /
1.212.466.6450
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Sep 2023 to Sep 2024